Overview

Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy

Status:
Unknown status
Trial end date:
2017-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Positive lymphoma patients treated with rituximab-based immunochemotherapy.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Peking University
Treatments:
Entecavir
Rituximab
Criteria
Inclusion Criteria:

- treatment-naive patients with B-cell lymphoma

- HBsAg positive at baseline

- treated with rituximab-based immunochemotherapy

- life expectancy of more than 3 months

Exclusion Criteria:

- younger than 18 years old

- HBsAg negative at baseline

- pregnant or lactating women